JP2025069284A5 - - Google Patents

Info

Publication number
JP2025069284A5
JP2025069284A5 JP2025013906A JP2025013906A JP2025069284A5 JP 2025069284 A5 JP2025069284 A5 JP 2025069284A5 JP 2025013906 A JP2025013906 A JP 2025013906A JP 2025013906 A JP2025013906 A JP 2025013906A JP 2025069284 A5 JP2025069284 A5 JP 2025069284A5
Authority
JP
Japan
Prior art keywords
antibody
composition
seq
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025013906A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025069284A (ja
Filing date
Publication date
Priority claimed from PCT/IB2020/053565 external-priority patent/WO2020212874A1/en
Application filed filed Critical
Publication of JP2025069284A publication Critical patent/JP2025069284A/ja
Publication of JP2025069284A5 publication Critical patent/JP2025069284A5/ja
Pending legal-status Critical Current

Links

JP2025013906A 2019-04-15 2025-01-30 乾癬性関節炎に罹患している対象者の治療方法 Pending JP2025069284A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IN201921015050 2019-04-15
IN201921015050 2019-04-15
IN202021004422 2020-01-31
IN202021004422 2020-01-31
PCT/IB2020/053565 WO2020212874A1 (en) 2019-04-15 2020-04-15 Methods for treatment of subjects with psoriatic arthritis
JP2021561000A JP7628962B2 (ja) 2019-04-15 2020-04-15 乾癬性関節炎に罹患している対象者の治療方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021561000A Division JP7628962B2 (ja) 2019-04-15 2020-04-15 乾癬性関節炎に罹患している対象者の治療方法

Publications (2)

Publication Number Publication Date
JP2025069284A JP2025069284A (ja) 2025-04-30
JP2025069284A5 true JP2025069284A5 (https=) 2025-10-17

Family

ID=72837755

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021561000A Active JP7628962B2 (ja) 2019-04-15 2020-04-15 乾癬性関節炎に罹患している対象者の治療方法
JP2025013906A Pending JP2025069284A (ja) 2019-04-15 2025-01-30 乾癬性関節炎に罹患している対象者の治療方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021561000A Active JP7628962B2 (ja) 2019-04-15 2020-04-15 乾癬性関節炎に罹患している対象者の治療方法

Country Status (16)

Country Link
US (1) US20220298233A1 (https=)
EP (1) EP3956357A4 (https=)
JP (2) JP7628962B2 (https=)
KR (1) KR20210140780A (https=)
CN (1) CN113825768A (https=)
AU (1) AU2020259375A1 (https=)
BR (1) BR112021020612A2 (https=)
CA (1) CA3143604A1 (https=)
IL (1) IL287213A (https=)
JO (1) JOP20210279A1 (https=)
MA (1) MA55729A (https=)
MX (1) MX2021012652A (https=)
MY (1) MY210310A (https=)
PH (1) PH12021552536A1 (https=)
SG (1) SG11202111056YA (https=)
WO (1) WO2020212874A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121843958A (zh) * 2023-08-11 2026-04-10 信达生物医药科技(杭州)有限公司 既往接受生物制剂治疗斑块状银屑病的受试者转用抗IL23p19抗体治疗斑块状银屑病的方法
AU2024338774A1 (en) * 2023-09-07 2026-03-26 Innovent Biologics (Suzhou) Co., Ltd. Method for treating moderate and severe psoriasis using recombinant anti-il-23p19 antibody
WO2026069253A1 (en) * 2024-09-30 2026-04-02 Sun Pharmaceutical Industries Limited Long term safety of tildrakizumab in psoriatic arthritis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807389B2 (en) * 2003-03-14 2010-10-05 University Of Rochester Methods and compositions related to joint inflammation diseases
WO2008063213A2 (en) * 2006-04-10 2008-05-29 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
ES2708988T3 (es) * 2007-02-23 2019-04-12 Merck Sharp & Dohme Anticuerpos anti-IL-23p19 obtenidos por ingeniería genética
EP2331078B1 (en) * 2008-08-27 2012-09-19 Merck Sharp & Dohme Corp. Lyophilized formulations of engineered anti-il-23p19 antibodies
MX2019000046A (es) * 2010-11-04 2023-10-05 Boehringer Ingelheim Int Anticuerpos anti-il-23.
ES2729603T3 (es) * 2012-06-27 2019-11-05 Merck Sharp & Dohme Anticuerpos IL-23 antihumanos cristalinos
UA117466C2 (uk) * 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19

Similar Documents

Publication Publication Date Title
JP2025069284A5 (https=)
JP2024075713A5 (https=)
JP2023052458A5 (https=)
JP2022177142A5 (https=)
JP2023517236A5 (https=)
JP2022105138A5 (https=)
FI101937B (fi) Menetelmä monoklonaalisen vasta-aineen tuottamiseksi, joka reagoi ihmi sen cachectiinin kanssa
US7041289B1 (en) Method for treating established spontaneous auto-immune diseases in mammals
JP6554155B2 (ja) Il−17アンタゴニストを使用して汎発性膿疱性乾癬(gpp)を処置する方法
JP2021517566A5 (https=)
JP2022532927A5 (https=)
JP2024174927A5 (https=)
JP2025032102A5 (https=)
JP2021526534A5 (https=)
JP2021505540A5 (https=)
JP2023538522A5 (https=)
JP4616291B2 (ja) インターフェロン−ガンマスティミュレーター含有医薬組成物
JP2021506817A5 (https=)
CN1154659C (zh) 新的抗艾滋病免疫毒素
EP2138513B1 (en) Pharmaceutical compositions of antibodies for diseases caused by viruses
JP2024507118A5 (https=)
JP2022529266A5 (https=)
JP2021523138A5 (https=)
JP2009538916A5 (https=)
JP2026062640A5 (https=)